C
Camp4 Therapeutics Corporation (CAMP)
NGM – Real vaqt narxi. Valyuta: USD
4.50
+0.10 (2.27%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.15
-0.35 (-7.77%)
Bozor oldidan: May 13, 2026, 7:34 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.50
+0.10 (2.27%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.15
-0.35 (-7.77%)
Bozor oldidan: May 13, 2026, 7:34 AM EDT
Camp4 Therapeutics Corporation, klinik bosqichdagi biofarmatsevtika kompaniyasi, bir qator genetik kasalliklarni davolash uchun RNK asosidagi dorilarni kashf qiladi va ishlab chiqadi. Uning yetakchi mahsulot nomzod CMP-001, siydik aylanishi buzilishlarini davolash uchun 1/2 bosqichli klinik sinovda. Kompaniya shuningdek, SYNGAP1 bilan bog'liq buzilishlarni davolash uchun CMP-002ni ishlab chiqmoqda. Camp4 Therapeutics Corporation ilgari Marauder Therapeutics, Inc. nomi bilan tanilgan va 2018-yil mart oyida Camp4 Therapeutics Corporation nomini o'zgartirgan. Kompaniya 2015-yilda ro'yxatga olingan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daniel Tardiff Ph.D. | Chief Scientific Officer |
| Dr. Leonard I. Zon M.D. | Founder & Chairman of Scientific Advisory Board |
| Dr. Richard A. Young Ph.D. | Founder & Independent Director |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
| Mr. Caleb Moore | Chief Business Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | camp-20260507.htm |
| 2026-04-23 | DEFA14A | defa14a-2026annualmeeting.htm |
| 2026-04-23 | DEF 14A | camp-20260422.htm |
| 2026-03-24 | 8-K | camp-20260318.htm |
| 2026-03-05 | 8-K | camp-20260305.htm |
| 2026-01-09 | 8-K | camp-20260109.htm |
| 2025-12-23 | 8-K | camp-20251222.htm |
| 2025-12-18 | 8-K | camp-20251218.htm |
| 2025-11-10 | S-3 | camp4therapeutics-atmsx3.htm |
| 2025-11-06 | 10-Q | camp-20250930.htm |
| Mr. Joshua Mandel-Brehm | CEO, President & Director |
| Ms. Alla Sigova Ph.D. | Senior Vice President of Platform |
| Ms. Kelly Gold | Chief Financial Officer |
| Ms. Michelle Gates | Senior VP & Chief People Officer |